WA
VIRX

Winfield Associates’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Winfield Associates’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed -$1K – 689
2017
Q4 		$1K Hold
1
– – ﹤0.01% 805
2017
Q3 		$0 Hold
1
– – ﹤0.01% 903
2017
Q2 		$0 Hold
1
– – ﹤0.01% 920
2017
Q1 		$0 Hold
1
– – ﹤0.01% 799
2016
Q4 		$0 Hold
1
– – ﹤0.01% 779
2016
Q3 		$0 Sell
1
-10
-91% -$1.41K ﹤0.01% 738
2016
Q2 		$1K Hold
11
– – ﹤0.01% 664
2016
Q1 		$1K Hold
11
– – ﹤0.01% 652
2015
Q4 		$2K Hold
11
– – ﹤0.01% 291
2015
Q3 		$2K Hold
11
– – ﹤0.01% 291
2015
Q2 		$7K Hold
11
– – ﹤0.01% 248
2015
Q1 		$5K Hold
11
– – ﹤0.01% 265
2014
Q4 		$6K Hold
11
– – ﹤0.01% 262
2014
Q3 		$16K Buy
11
+5
+83% +$7.24K 0.01% 213
2014
Q2 		$7K Buy
+6
New +$6.96K 0.01% 260
2014
Q1 		– Hold
0
– – – 291

Other funds holding VIRX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Winfield Associates's VIRX Position: Q1 2018 in Review

Winfield Associates sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2018, closing a stake of 1 share — an estimated $1K sold.

Winfield Associates first reported a position in VIRX in Q2 2014 and held it in 15 quarters. The position peaked at $16K in Q3 2014. 50 funds tracked by Wall St. Rank hold VIRX as of Q1 2018.

  • Winfield Associates reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 1 Viracta Therapeutics, Inc. Common Stock share in Q1 2018, an estimated $1K.
  • Winfield Associates first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 15 quarters.
  • Winfield Associates's Viracta Therapeutics, Inc. Common Stock position peaked at $16K in Q3 2014.
  • 50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.